Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 8/20 | 0.55 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.51 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.51 |
| ▸ | ATR | Q13535 | 4/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.48 |
| ▸ | CDK2AP1 | O14519 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460859 | 0.92 | TYRO3 (0.52) | TYRO3ACVR2ATGFBR2ATRACVR1 | |
| SCHEMBL3460004 | 0.91 | TYRO3 (0.53) | TYRO3ACVR2ATGFBR2ATRACVR1 | |
| SCHEMBL3460835 | 0.91 | TYRO3 (0.65) | TYRO3ACVR2ATGFBR2ATRACVR1 | |
| SCHEMBL3462056 | 0.90 | CHEK1 (0.62) | TYRO3ACVR2ATGFBR2ATRACVR1 | |
| SCHEMBL3460506 | 0.86 | TYRO3 (0.57) | TYRO3ACVR2ATGFBR2ATRACVR1 | |
| SCHEMBL3459906 | 0.85 | TYRO3 (0.55) | TYRO3ACVR2ATGFBR2ATRACVR1 | |
| SCHEMBL3460301 | 0.85 | TYRO3 (0.61) | TYRO3ACVR2ATGFBR2ATRACVR1 | |
| SCHEMBL3461287 | 0.85 | ATR (0.61) | TYRO3ACVR2ATGFBR2ATRACVR1 | |
| SCHEMBL3460685 | 0.84 | ACVR1 (0.50) | TYRO3ATRACVR1 | |
| SCHEMBL3461206 | 0.84 | TYRO3 (0.53) | TYRO3ACVR2ATGFBR2ATRACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | TYRO3 790/4885ACVR2A 2128/4885TGFBR2 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.